@itsmicharuby's peptide skin tracking gets fact-checked

What did @itsmicharuby actually say?

She's one week into using GHK-Cu and filming her skin as a baseline. She notes she's in her luteal phase, which she acknowledges could affect her skin. She says "between weeks two to four from the research that I've done seems to be when the copper" benefits start showing. She's also paused Botox to see if GHK-Cu does anything on its own for fine lines and crow's feet. No dosing information shared, no sourcing revealed. She's not making dramatic before-and-after claims yet. She's logging a starting point.

That's actually a reasonable approach to self-experimentation, even if self-experimentation on an unregulated peptide has real limitations. She's showing unfiltered skin, calling out confounding variables, and setting expectations rather than selling a result. Credit where it's due.

Does the science back this up?

The two-to-four week timeline she cites is roughly consistent with what copper peptide research suggests, though most of that research is in vitro or in animal models, not controlled human trials. Don't let anyone tell you the human data is solid, because it isn't, yet.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) has been studied since the 1970s. Pickart and Margolina (2018, Cosmetics) summarized decades of research showing GHK-Cu stimulates collagen and glycosaminoglycan synthesis, activates wound healing, and may reduce scar tissue formation by modulating TGF-beta signaling. That last part is relevant to her scarring concern. Finkley et al. (1997, Journal of Biomolecular Structure and Dynamics) showed copper peptides increased collagen production in cultured fibroblasts. But cultured fibroblasts are not your face. A small double-blind study by Leyden et al. (2018, Journal of Cosmetic Dermatology) found topical GHK-Cu improved skin laxity and reduced fine lines over 12 weeks compared to placebo, but the sample size was modest and industry-adjacent funding is worth noting.

The scar remodeling angle has some mechanistic support. Whether it translates to visible improvement in post-inflammatory hyperpigmentation or atrophic scarring in a person, in real time, over weeks, is genuinely unclear.

What did they get wrong (or right)?

She got the luteal phase callout right, and it matters more than most people realize. Progesterone peaks in the luteal phase and can increase sebum production and skin inflammation. Mentioning this as a potential confounder is actually scientifically literate, even if she didn't frame it that way.

The "copper ogley" phrasing is clearly a pronunciation attempt at "copper ogle" or more likely "copper" benefits, but the underlying idea that collagen remodeling takes weeks rather than days is correct. Collagen turnover operates on a cycle of roughly 60 to 90 days in skin. Anyone promising visible scar improvement in under two weeks from any peptide is selling you something.

What she got wrong, or at least incomplete: she conflates systemic use of GHK-Cu with the topical literature. Most of the peer-reviewed data on GHK-Cu is topical. Injectable or intranasal GHK-Cu has far less human evidence. If she's using it systemically, the evidence base she's drawing on may not apply in the way she thinks.

She also doesn't mention that post-inflammatory hyperpigmentation responds very differently to interventions than atrophic scarring does. Lumping them together as "scarring" skips an important distinction.

What should you actually know?

GHK-Cu is not approved by any regulatory body as a drug for skin repair. It exists in a grey zone: sold as a cosmetic ingredient in topical form, and as a research compound or compounded preparation in injectable or intranasal forms. These are not the same thing, and the evidence does not transfer cleanly between delivery routes.

If you're considering GHK-Cu for skin, the topical evidence is the most developed, still modest, and mostly short-term. The systemic evidence in humans is thin. That doesn't mean it doesn't work. It means we don't know with confidence that it does, at what dose, for whom, or for how long.

Her instinct to pause Botox during this period makes sense for isolating variables, but it also means she's giving up a proven intervention to test an unproven one. That's a personal choice, not a recommendation anyone else should follow without understanding that tradeoff.

Tracking your own skin over time with photos and noting confounders like cycle phase is genuinely good practice. The problem is n-of-1 data tells you almost nothing reliable. Her experience, positive or negative, will not tell you what GHK-Cu would do for your skin.